<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053819</url>
  </required_header>
  <id_info>
    <org_study_id>F070629011</org_study_id>
    <nct_id>NCT01053819</nct_id>
  </id_info>
  <brief_title>Can We Miss Pigmented Lesions in Psoriasis Patients?</brief_title>
  <official_title>Can We Miss Pigmented Lesions in Psoriasis Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians
      rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions.
      However, successful systemic treatment and subsequent clearing of psoriatic plaques may
      allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of
      early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and
      malignant melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No further description is desired.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.</measure>
    <time_frame>Patients will complete study within 6 months.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria</measure>
    <time_frame>Patients will complete the study within 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Psoriasis</condition>
  <condition>Melanoma</condition>
  <condition>Non-melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of moderate to severe plaque psoriasis identified by a BSA greater than or
             equal to 10% and a Psoriasis Area and Severity Index score greater than or equal to
             12

          2. Age 19 years or above

          3. Fitzpatrick skin type I, II or III

          4. Candidate for systemic treatment in the opinion of the investigator

          5. Willingness to undergo treatment with Enbrel as outlined above

          6. Negative pregnancy test (urine or serum Î²-Human Chorionic Gonadotrophin ) before the
             first dose of study drug in all women (except those surgically sterile, or at least 5
             years postmenopausal).

          7. Negative Tuberculosis skin test at entry into the study or a negative screening x-ray
             in inconclusive Purified Protein Derivative reading (borderline, reactive but
             non-diagnostic) or in prior bacille Calmette-Guerin inoculated subjects.

          8. Sexually active subjects of childbearing potential must agree to use medically
             acceptable form of contraception during screening and throughout the study

          9. Subject or designee must have the ability to self-inject study medication or have a
             care giver at home who can administer subcutaneous injections

         10. Must be able and willing to give written informed consent and comply with the
             requirements of the study protocol and must authorize release and use of protected
             health information

        Exclusion Criteria:

          1. Serum creatinine &gt; 3.0 mg/dL (265 micromoles/L)

          2. Serum potassium &lt; 3.5 mmol/L or &gt; 5.5 mmol/L

          3. Serum alanine aminotransferase or Aspartate transaminase &gt; 3 times the upper limit of
             normal for the Lab

          4. Platelet count &lt; 100,000/mm3

          5. White blood cell count &lt; 3,000 cells/mm3

          6. Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower
             limits of normal for the Lab

          7. Systemic therapy use (e.g. phototherapy, methotrexate, cyclosporine, oral steroids,
             systemic biologics) within the previous 4 weeks

          8. Topical therapy use (e.g. topical steroids, vitamin D derivatives) within the
             previous 2 weeks

          9. Subject is currently enrolled in another investigational device or drug trial(s), or
             subject has received other investigational agent(s) within 28 days of baseline visit.

         10. Subjects who have known hypersensitivity to Enbrel or any of its components or who is
             known to have antibodies to etanercept

         11. Prior or concurrent cyclophosphamide therapy

         12. Concurrent sulfasalazine therapy

         13. Known Human immunodeficiency virus-positive status or known history of any other
             immunosuppressing disease

         14. Active severe infections within 4 weeks before screening visit, or between the
             screening and baseline visits

         15. Untreated Lyme disease

         16. Severe comorbidities (diabetes mellitus requiring insulin, CHF of any severity, MI,
             CVA or TIA within 3 months of screening visit, unstable angina pectoris, uncontrolled
             hypertension (sitting systolic BP &lt;80 mm Hg or &gt; 160 or diastolic BP &gt; 100 mm Hg),
             oxygen-dependent severe pulmonary disease, history of cancer within 5 years [other
             than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer])

         17. History of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of
             multiple sclerosis, transverse myelitis, optic neuritis or epilepsy

         18. History of recent alcohol or substance abuse (&lt; 1 year)

         19. Pregnant or lactating females

         20. Use of a live vaccine 90 days prior to, or during this study

         21. Any condition judged by the patient's physician to cause this clinical trial to be
             detrimental to the patient

         22. History of non-compliance with other therapies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boni E Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Dermatology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>August 21, 2012</lastchanged_date>
  <firstreceived_date>February 6, 2009</firstreceived_date>
  <firstreceived_results_date>May 1, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Boni Elewski, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>melanoma</keyword>
  <keyword>non-melanoma skin cancer</keyword>
  <keyword>etanercept</keyword>
  <keyword>Enbrel</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>Patients will receive six months of treatment with Enbrel 50mg SC given twice a week for the first three months and 50 mg once a week thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>open label treatment per FDA approval for 24 weeks</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.</title>
        <time_frame>Patients will complete study within 6 months.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>open label treatment per FDA approval for 24 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria</title>
        <time_frame>Patients will complete the study within 6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etanercept</title>
          <description>open label treatment per FDA approval for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boni Elewski, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-502-9960</phone>
      <email>beelewski@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
